The global anti-neoplastic agents market is poised to reach around USD 150 billion by 2022, at a
striking CAGR of 8% during the forecast period (2016-2022).
The increasing geriatric population, the alarming prevalence of diseases due to lifestyle changes
and the need for cost-effective cancer cures are the key drivers of the anti-neoplastic market
and are poised to contribute significantly to the growth of the market over the forecast period.
The development of the demand for anti-neoplastic agents has been fueled by the new cases of
neoplasms worldwide, rising spending by government agencies worldwide, and attractive
Request Sample Copy:
Growing cancer cases along with demand for cost-effective treatments was due to market
growth over the projected time frame. It is expected that breakthroughs in the customised
medicine domain will deliver new development avenues over the projected timeframe for the
anti-neoplastic agents industry. Ses medications are used in radiotherapies, surgeries, hormone
therapies, among other different targeted therapies in conjunction with other medication
therapies and this would push consumer patterns. Nevertheless in developing markets as well
as underdeveloped countries, low levels of understanding of cancer symptoms will pose a
danger to the sector's growth over the projected era. Apparently, in the near future, high prices
for the production of drugs would hinder business growth.
The Global Anti-neoplastic agents market has been segmented on the basis of type comprises
antitumor antibiotics, alkylating and alkylating-like agents, antimetabolites, plant alkaloids,
hormonal agents, and miscellaneous agents.
On the basis of end users, the market is segmented into research institutes, hospitals, clinics,
cancer rehabilitation centers and others.
The largest demand for anti-neoplastic agents in